secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-08-06T20:06:49+00:00
Accession:  0001437749-26-026256
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q2 net loss $24.7M; NANOPULSE-AF enrollment ahead of schedule
-------------------------------------------------------------------------------

- Q2 revenue $0.4M; GAAP net loss ($24.7M) vs ($19.2M) year ago; non-GAAP net loss ($19.4M).
- Cash $101.6M at June 30, 2026; raised $46.8M net via ATM in Q2, plus $10.7M post-quarter.
- NANOPULSE-AF pivotal study surpassed 82 evaluable patients; enrollment target raised to 164, completion expected early Q4.
- New $75M ATM facility in place; shelf registration for additional $125M provides financing flexibility.
- Soft tissue revenue $434k, sequential growth; PRECISE-BTN study to complete enrollment within month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926026256/0001437749-26-026256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926026256/plse20260518_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer